title: Prevalence and clinical characteristics of adult patients with congenital heart disease in Tuscany.
abstract: OBJECTIVE
  The clinical features of the adult population with congenital heart disease (CHD) are still not well characterized, particularly in the subset with more severe lesions. We report the data collected in the National Association of Hospital Cardiologists Toscana grown-up CHD (GUCH) registry over its first 8-month enrolment period.
  
  
  METHODS
  The Registry included consecutive patients aged more than 16 years with a documented diagnosis of CHD, enrolled in seven different Tuscan hospitals using a web-based electronic form. Severe CHD was defined as cyanotic CHD, or acyanotic lesion with significant haemodynamic impact requiring surgical and/or percutaneous correction.
  
  
  RESULTS
  Between November 2009 and June 2010 a total of 1641 patients (mean age 41.8 ± 19.3 years, 52.2% women) were enrolled. Atrial septal defect was the most common lesion, accounting for more than one-third of cases. Atrial and ventricular septal defects together accounted for about half of all CHDs. Nearly one-third of patients had New York Heart Association (NYHA) class 2 or more. A history of recurrent arrhythmias was reported in 15% of cases, and 12% of patients were on oral anticoagulants at the time of enrolment. The prevalence of pulmonary hypertension was 6%, and the prevalence of Eisenmenger syndrome was 1.2%. Severe CHD was present in 42% of patients. Younger age, higher NYHA class, male sex, and the need for oral anticoagulants were the only independent predictors of severe CHD.
  
  
  CONCLUSIONS
  Information about the clinical characteristics and the CHD type distribution of a sample of Tuscan GUCH population was provided. Severe CHD accounts for about 40% of all CHDs in this population. CHD severity is associated with younger age, male gender, worse NYHA class, and need for oral anticoagulation.
authors.affiliation: UOC Cardiologia, AOU A.Meyer, Firenze, Italy. s.favilli@meyer.it
authors.forename: Silvia
authors.initials: S
authors.lastname: Favilli
authors.forename: Gennaro
authors.initials: G
authors.lastname: Santoro
authors.forename: Piercarlo
authors.initials: P
authors.lastname: Ballo
authors.forename: Chiara
authors.initials: C
authors.lastname: Arcangeli
authors.forename: Francesco M
authors.initials: FM
authors.lastname: Bovenzi
authors.forename: Enrico
authors.initials: E
authors.lastname: Chiappa
authors.forename: Umberto
authors.initials: U
authors.lastname: Conti
authors.forename: Anna
authors.initials: A
authors.lastname: Monopoli
authors.forename: Bruno
authors.initials: B
authors.lastname: Murzi
authors.forename: Costanza
authors.initials: C
authors.lastname: Rosini
authors.forename: Alfredo
authors.initials: A
authors.lastname: Zuppiroli
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000925:Anticoagulants / Q000008:administration & dosage; D005260:Female; D006330:Heart Defects, Congenital / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D006801:Humans; D007558:Italy / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011379:Prognosis; D012042:Registries; D012111:Residence Characteristics; D012307:Risk Factors; D012720:Severity of Illness Index; D012737:Sex Factors; D013997:Time Factors; D055815:Young Adult
chemical_list: D000925:Anticoagulants